EMA Application withdrawn: Hervelous (trastuzumab) — Prestige Biopharma Belgium

View source ↗

Summary

The EMA indicates an application for Hervelous (trastuzumab) by Prestige Biopharma Belgium has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Stomach Neoplasms

Drugs mentioned

• Hervelous (trastuzumab)

Snippet

Status: Application withdrawn. Therapeutic area: Stomach Neoplasms;Breast Neoplasms. MAH: Prestige Biopharma Belgium